Equities

Shanghai Aladdin Biochemical Technology Co Ltd

688179:SHH

Shanghai Aladdin Biochemical Technology Co Ltd

Actions
Basic MaterialsChemicals
  • Price (CNY)10.00
  • Today's Change-5.64 / -36.06%
  • Shares traded1.66m
  • 1 Year change-33.59%
  • Beta1.8197
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Aladdin Biochemical Technology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of scientific research reagents. The Company's businesses cover the four major areas of high-end chemistry, life sciences, analytical chromatography and materials science, and a small amount of experimental consumables. The Company's products are used in universities, scientific research institutes, biomedicine, new materials, new energy, energy conservation and environmental protection, aerospace and other fields. The Company independently builds Aladdin brand scientific research reagents and Silicon Valley brand experimental consumables, mainly relying on its own e-commerce platform www.aladdin-e.com to achieve online sales. The Company mainly conducts its businesses in the China market.

  • Revenue in CNY (TTM)497.71m
  • Net income in CNY103.71m
  • Incorporated2009
  • Employees566.00
  • Location
    Shanghai Aladdin Biochemical Technology Co Ltd16F, South Tower, No. 36Xinjinqiao Road, Pudong New AreaSHANGHAI 201206ChinaCHN
  • Phone+86 2 150560989
  • Fax+86 2 150323701
  • Websitehttps://www.aladdin-e.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
688179:SHH since
announced
Transaction
value
Shanghai Yuanye Bio-Technology Co LtdDeal completed19 Mar 202419 Mar 2024Deal completed-6.45%25.13m
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Xinjiang Bai Hua Cun Pharma Tech Co Ltd394.19m19.23m2.84bn787.00147.213.83--7.190.05030.05031.031.930.3631.631.77500,882.401.77-4.592.50-6.2446.2924.094.88-18.401.46--0.0006--5.54-2.50137.33---21.00--
Qingdao Vland Biotech INC1.26bn66.23m3.61bn1.57k54.172.09--2.850.26310.26315.026.830.4253.783.76805,143.803.255.785.097.8944.9846.137.6510.340.924811.630.290433.593.078.0515.56-0.650724.68-6.89
Hinova Pharmaceuticals Inc109.74k-210.18m3.75bn179.00--3.05--34,214.25-2.12-2.120.001112.440.000077.120.0805613.07-14.10-31.86-15.71-37.18-450.31---191,529.30-25,578.246.38--0.0457---100.00--2.44--124.37--
Bide Pharmatech Co Ltd1.10bn80.03m4.04bn846.0049.542.02--3.680.89830.898312.2521.980.46080.93594.511,298,144.003.34--3.82--40.11--7.25--4.59--0.0492--30.94---24.94------
Shanghai Aladdin Biochemical Tech Co Ltd497.71m103.71m4.34bn566.0035.234.17--8.720.44390.44391.983.750.31030.38189.08879,345.607.208.838.229.6161.5761.4923.2126.853.10113.470.278145.716.5519.36-7.489.9531.41--
Jiangsu Yahong Meditech Co Ltd149.71m-403.23m4.53bn394.00--2.18--30.27-0.7074-0.70740.26273.650.059816.646.92379,971.80-16.14-15.80-17.15-16.4878.6355.32-269.87-9,445.918.97--0.0599--52,594.79---62.42--64.28--
Beijing Kawin Technol Sha-hld Co Ltd1.42bn134.34m4.70bn584.0033.632.53--3.310.81750.81758.5310.870.57361.803.272,431,971.006.495.318.526.7681.8086.0211.318.102.91--0.14143.8221.7314.8739.7121.0425.01--
Beijing Sun-Novo Pharma Research Co Ltd1.16bn221.37m5.03bn1.39k22.724.45--4.351.981.9810.3310.100.607935.951.77844,377.1011.2512.9918.7621.7053.3053.9318.5021.341.8629.920.306810.7437.7647.2218.0854.9034.77--
Shanghai Medicilon Inc984.17m-276.79m5.20bn2.42k--2.21--5.28-2.01-2.017.2317.460.30296.901.27378,525.60-8.529.34-10.6611.730.644336.71-28.1214.932.64--0.114720.18-17.6833.26-109.82--23.60--
HitGen Inc423.87m52.55m5.53bn452.00104.994.01--13.050.13140.13141.063.440.2487.104.55937,755.302.994.633.165.1051.2358.8912.0520.6616.1538.230.139119.1412.6419.6961.16-1.96-6.12--
GemPharmatech Co Ltd677.34m139.41m5.62bn1.51k39.942.64--8.290.3430.3431.655.200.27034.542.06449,761.405.569.456.3911.1363.0470.2120.5828.164.74--0.050914.6820.4563.48-3.48--141.38--
Data as of Sep 13 2024. Currency figures normalised to Shanghai Aladdin Biochemical Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.76%Per cent of shares held by top holders
HolderShares% Held
Huashang Fund Management Co., Ltd.as of 30 Jun 20245.36m1.93%
GF Fund Management Co., Ltd.as of 30 Jun 2024656.63k0.24%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024489.29k0.18%
Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2024454.08k0.16%
Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024219.00k0.08%
Gfund Management Co., Ltd.as of 30 Jun 2024206.86k0.08%
JX Asset Management Co.,Ltdas of 30 Jun 202499.95k0.04%
Penghua Fund Management Co., Ltd.as of 30 Jun 202461.90k0.02%
Wanjia Asset Management Co., Ltd.as of 30 Jun 202461.00k0.02%
First Seafront Fund Management Co., Ltd.as of 30 Jun 202457.04k0.02%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.